Synthesis of N-Butyl Side Chain Hydroxylated Metabolites of Roxifiban, a Platelet Glycoprotein IIb/IIIa Receptor Antagonist
摘要:
Syntheses of three n-butyl side chain hydroxylated metabolites of Roxifiban (5, 6a and 6b) are reported. Initial use of benzyl as hydroxyl protecting group gave poor yield during its removal by catalytic hydrogenation, due to complication from N-O cleavage of the isoxazoline. This problem was eliminated by the use of TBDMS as the hydroxyl protecting group. The chemical structures of these metabolites as well as the intermediates have been fully characterized.
Synthesis of N-Butyl Side Chain Hydroxylated Metabolites of Roxifiban, a Platelet Glycoprotein IIb/IIIa Receptor Antagonist
摘要:
Syntheses of three n-butyl side chain hydroxylated metabolites of Roxifiban (5, 6a and 6b) are reported. Initial use of benzyl as hydroxyl protecting group gave poor yield during its removal by catalytic hydrogenation, due to complication from N-O cleavage of the isoxazoline. This problem was eliminated by the use of TBDMS as the hydroxyl protecting group. The chemical structures of these metabolites as well as the intermediates have been fully characterized.
Synthesis of N-Butyl Side Chain Hydroxylated Metabolites of Roxifiban, a Platelet Glycoprotein IIb/IIIa Receptor Antagonist
作者:Jung-Hui Sun、George C. Emmett、Janice L. Hytrek、Jia-Sheng Yan、A. Christine Tabaka-Blom、Christopher A. Teleha
DOI:10.3987/com-04-10087
日期:——
Syntheses of three n-butyl side chain hydroxylated metabolites of Roxifiban (5, 6a and 6b) are reported. Initial use of benzyl as hydroxyl protecting group gave poor yield during its removal by catalytic hydrogenation, due to complication from N-O cleavage of the isoxazoline. This problem was eliminated by the use of TBDMS as the hydroxyl protecting group. The chemical structures of these metabolites as well as the intermediates have been fully characterized.